Scinai Immunotherapeutics to Participate in BIO-Europe Spring 2026
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1 hour ago
0mins
Should l Buy SCNI?
Scinai Immunotherapeutics announced its participation in BIO-Europe Spring 2026, taking place March 23-25 in Lisbon, Portugal. During the conference, the team will meet with pharmaceutical and biotechnology companies, investors, and prospective clients to advance both Scinai's innovative R&D pipeline and its integrated CDMO offering. "BIO-Europe Spring marks an important milestone for Scinai as we present our expanded capabilities following the Recipharm transaction," said Amir Reichman, Chief Executive Officer of Scinai. "We are uniquely positioned to partner with biotech and pharma companies across the full lifecycle of their products, from early-stage development through clinical and into commercial manufacturing, while also advancing a differentiated pipeline of immunology therapeutics. We look forward to engaging with partners who are seeking both innovation and execution."
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy SCNI?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on SCNI
About SCNI
Scinai Immunotherapeutics Ltd, formerly known as BiondVax Pharmaceuticals Ltd is an Israel-based biopharmaceutical company that is principally focused on developing, manufacturing, and commercializing medical products for the prevention and treatment of autoimmune and infectious diseases but also for other illnesses. The Company’s core focus is to develop NanoAbs for the treatment of various diseases such as COVID-19, psoriasis, and asthma. The Company's product NanoAb is based on alpaca-derived nanosized antibodies (NanoAbs), also known as VHH-antibodies. Additionally, the Company offers manufacturing facilities, aseptic fill and finish suites, laboratories, and experienced professionals for other research and development companies. Scinai Immunotherapeutics Ltd operates in Israel.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Scinai Immunotherapeutics to Participate in BIO-Europe Spring 2026
- International Conference Participation: Scinai Immunotherapeutics will showcase at BIO-Europe Spring 2026 from March 23-25 in Lisbon, marking its first major international conference following the acquisition of Recipharm Israel, which significantly expands its development and manufacturing capabilities.
- CDMO Platform Advantage: Through its subsidiary Scinai Biopharma Services Ltd., the company offers an integrated CDMO platform from early development to commercialization, leveraging cGMP biologics and small-molecule API development sites in Jerusalem and Yavne, enhancing collaboration potential with biotech and pharmaceutical firms.
- Advancing Antibody Therapy Pipeline: Scinai will present its innovative antibody-based therapeutics pipeline targeting autoimmune and inflammatory diseases, primarily focusing on dermatology, while actively seeking strategic partnerships, co-development, and licensing opportunities with pharmaceutical and biotech companies to advance its pipeline.
- Market Positioning and Strategic Collaboration: CEO Amir Reichman stated that Scinai aims to partner with biotech and pharma companies across all product lifecycle stages, focusing on innovation and execution to meet market demands and further enhance the company's competitive edge.
See More
Scinai Immunotherapeutics Receives Nasdaq Compliance Notice
- Compliance Notice: Scinai Immunotherapeutics received a notification from Nasdaq indicating non-compliance with the minimum bid price requirement, as its American Depositary Shares closed below $1.00 for 30 consecutive business days.
- Compliance Period: The company has been granted 180 calendar days until September 8, 2026, to regain compliance, and if its ADS closing price reaches at least $1.00 for a minimum of 10 consecutive business days during this period, Nasdaq will confirm compliance.
- Stock Price Movement: Following the notification, Scinai's ADS closed down 1.46% at $0.7, reflecting market sensitivity to compliance issues, which may impact investor confidence.
- Trading Impact: The notification does not have an immediate effect on the listing or trading of the company's shares, indicating that the company still has time to take measures to restore compliance.
See More
Scinai Immunotherapeutics Seeks €12 Million Grant for R&D Program
- Funding Application Progress: Scinai Immunotherapeutics has submitted a revised application seeking €12 million in non-dilutive funding to support a €15 million R&D program for PC111, with a funding decision expected within three to four months, thereby providing crucial financial backing for treating severe autoimmune blistering diseases.
- Timeline Adjustments: The Second Amendment to the agreement extends the deadline for fulfilling option conditions to August 31, 2026, and the option exercise period to September 30, 2026, ensuring alignment with the grant evaluation process and enhancing the project's feasibility.
- Clinical Development Advancement: If awarded, the grant would enable Scinai to advance PC111 through early clinical development and human proof of concept while preserving balance sheet flexibility and minimizing shareholder dilution, strategically laying the groundwork for future R&D initiatives.
- Strengthened Innovation Framework: The revised application reflects structural enhancements to project design and translational scope, aiming to advance PC111 through a milestone-driven framework, ensuring competitiveness in regulatory pathways given the high unmet medical need.
See More
Scinai Immunotherapeutics Seeks €12 Million Grant for R&D Program
- Funding Application Progress: Scinai Immunotherapeutics has submitted a revised application seeking €12 million in non-dilutive funding to support a €15 million R&D program for PC111, with a funding decision expected in approximately three to four months, thereby accelerating treatment development for severe autoimmune diseases.
- Timeline Adjustments: The Second Amendment extends the deadline for fulfilling option conditions to August 31, 2026, and the option exercise period to September 30, 2026, ensuring alignment with the grant evaluation process and enhancing project feasibility.
- Enhanced Competitiveness: The revised SMART Path program application reflects structural enhancements to project design and translational scope, aiming to advance PC111 through a milestone-driven framework that culminates in integrated non-clinical and First-in-Human datasets to support data-driven progression decisions.
- Strategic Flexibility: If awarded, the grant would enable Scinai to advance PC111 through early clinical development while preserving balance sheet flexibility and minimizing shareholder dilution, ensuring a leading position in a market with high unmet medical needs.
See More
Scinai Secures Expanded Support from Israel Innovation Authority
- Expanded Funding Support: Scinai Immunotherapeutics has received approval for a NIS 5 million grant from the Israel Innovation Authority, with approximately 66% being non-dilutive funding, aimed at enhancing its aseptic fill and finish platform capabilities, thereby strengthening its competitive position in the biopharmaceutical sector.
- Technology Upgrade Initiative: The project will support the acquisition and validation of a fully automated robotic aseptic fill system, with validation targeted for completion in Q3 2026, aligning with EU GMP Annex 1 standards, significantly improving production consistency and contamination control.
- Deepening Strategic Collaboration: Following the acquisition of Recipharm Israel and the signing of a strategic commercial collaboration agreement, Scinai establishes an integrated development and manufacturing platform across its Jerusalem and Yavne sites, further solidifying its position as a technology-driven contract development and manufacturing organization (CDMO) partner.
- Future Development Outlook: Scinai is monitoring an upcoming industrial CAPEX support program from the Israel Innovation Authority, which, if approved, would enhance capabilities at its Yavne small-molecule site, aiding the implementation of its CDMO expansion strategy.
See More
Scinai CEO to Co-Lead Biopharma Roundtable at HealthIL Week 2026
- Industry Discussion: Scinai's CEO Amir Reichman will co-lead a roundtable on January 19, 2026, during HealthIL Week in Tel Aviv, focusing on Israel's biopharma manufacturing capabilities and their impact on the industry, particularly in early development and clinical manufacturing.
- Manufacturing Capability Assessment: The roundtable will examine the current state of Israel's biopharma development ecosystem, emphasizing GMP manufacturing for clinical supply amidst increasing global complexity in biopharma manufacturing, highlighting the need for enhanced local capabilities.
- Diverse Participation: Representatives from government, public agencies, international biopharma manufacturers, and investors are expected to participate, fostering in-depth dialogue and collaboration on the future development of Israel's biopharma sector.
- Strategic Importance: By discussing the infrastructure and manufacturing capabilities in Israel's biopharma sector, the roundtable aims to provide practical insights that will help companies maintain competitiveness and attract investment over the next 5-10 years.
See More
Scinai Immunotherapeutics to Participate in BIO-Europe Spring 2026
- International Conference Participation: Scinai Immunotherapeutics will showcase at BIO-Europe Spring 2026 from March 23-25 in Lisbon, marking its first major international conference following the acquisition of Recipharm Israel, which significantly expands its development and manufacturing capabilities.
- CDMO Platform Advantage: Through its subsidiary Scinai Biopharma Services Ltd., the company offers an integrated CDMO platform from early development to commercialization, leveraging cGMP biologics and small-molecule API development sites in Jerusalem and Yavne, enhancing collaboration potential with biotech and pharmaceutical firms.
- Advancing Antibody Therapy Pipeline: Scinai will present its innovative antibody-based therapeutics pipeline targeting autoimmune and inflammatory diseases, primarily focusing on dermatology, while actively seeking strategic partnerships, co-development, and licensing opportunities with pharmaceutical and biotech companies to advance its pipeline.
- Market Positioning and Strategic Collaboration: CEO Amir Reichman stated that Scinai aims to partner with biotech and pharma companies across all product lifecycle stages, focusing on innovation and execution to meet market demands and further enhance the company's competitive edge.
See More
Scinai Immunotherapeutics Receives Nasdaq Compliance Notice
- Compliance Notice: Scinai Immunotherapeutics received a notification from Nasdaq indicating non-compliance with the minimum bid price requirement, as its American Depositary Shares closed below $1.00 for 30 consecutive business days.
- Compliance Period: The company has been granted 180 calendar days until September 8, 2026, to regain compliance, and if its ADS closing price reaches at least $1.00 for a minimum of 10 consecutive business days during this period, Nasdaq will confirm compliance.
- Stock Price Movement: Following the notification, Scinai's ADS closed down 1.46% at $0.7, reflecting market sensitivity to compliance issues, which may impact investor confidence.
- Trading Impact: The notification does not have an immediate effect on the listing or trading of the company's shares, indicating that the company still has time to take measures to restore compliance.
See More
Scinai Immunotherapeutics Seeks €12 Million Grant for R&D Program
- Funding Application Progress: Scinai Immunotherapeutics has submitted a revised application seeking €12 million in non-dilutive funding to support a €15 million R&D program for PC111, with a funding decision expected within three to four months, thereby providing crucial financial backing for treating severe autoimmune blistering diseases.
- Timeline Adjustments: The Second Amendment to the agreement extends the deadline for fulfilling option conditions to August 31, 2026, and the option exercise period to September 30, 2026, ensuring alignment with the grant evaluation process and enhancing the project's feasibility.
- Clinical Development Advancement: If awarded, the grant would enable Scinai to advance PC111 through early clinical development and human proof of concept while preserving balance sheet flexibility and minimizing shareholder dilution, strategically laying the groundwork for future R&D initiatives.
- Strengthened Innovation Framework: The revised application reflects structural enhancements to project design and translational scope, aiming to advance PC111 through a milestone-driven framework, ensuring competitiveness in regulatory pathways given the high unmet medical need.
See More
Scinai Immunotherapeutics Seeks €12 Million Grant for R&D Program
- Funding Application Progress: Scinai Immunotherapeutics has submitted a revised application seeking €12 million in non-dilutive funding to support a €15 million R&D program for PC111, with a funding decision expected in approximately three to four months, thereby accelerating treatment development for severe autoimmune diseases.
- Timeline Adjustments: The Second Amendment extends the deadline for fulfilling option conditions to August 31, 2026, and the option exercise period to September 30, 2026, ensuring alignment with the grant evaluation process and enhancing project feasibility.
- Enhanced Competitiveness: The revised SMART Path program application reflects structural enhancements to project design and translational scope, aiming to advance PC111 through a milestone-driven framework that culminates in integrated non-clinical and First-in-Human datasets to support data-driven progression decisions.
- Strategic Flexibility: If awarded, the grant would enable Scinai to advance PC111 through early clinical development while preserving balance sheet flexibility and minimizing shareholder dilution, ensuring a leading position in a market with high unmet medical needs.
See More
Scinai Secures Expanded Support from Israel Innovation Authority
- Expanded Funding Support: Scinai Immunotherapeutics has received approval for a NIS 5 million grant from the Israel Innovation Authority, with approximately 66% being non-dilutive funding, aimed at enhancing its aseptic fill and finish platform capabilities, thereby strengthening its competitive position in the biopharmaceutical sector.
- Technology Upgrade Initiative: The project will support the acquisition and validation of a fully automated robotic aseptic fill system, with validation targeted for completion in Q3 2026, aligning with EU GMP Annex 1 standards, significantly improving production consistency and contamination control.
- Deepening Strategic Collaboration: Following the acquisition of Recipharm Israel and the signing of a strategic commercial collaboration agreement, Scinai establishes an integrated development and manufacturing platform across its Jerusalem and Yavne sites, further solidifying its position as a technology-driven contract development and manufacturing organization (CDMO) partner.
- Future Development Outlook: Scinai is monitoring an upcoming industrial CAPEX support program from the Israel Innovation Authority, which, if approved, would enhance capabilities at its Yavne small-molecule site, aiding the implementation of its CDMO expansion strategy.
See More
Scinai CEO to Co-Lead Biopharma Roundtable at HealthIL Week 2026
- Industry Discussion: Scinai's CEO Amir Reichman will co-lead a roundtable on January 19, 2026, during HealthIL Week in Tel Aviv, focusing on Israel's biopharma manufacturing capabilities and their impact on the industry, particularly in early development and clinical manufacturing.
- Manufacturing Capability Assessment: The roundtable will examine the current state of Israel's biopharma development ecosystem, emphasizing GMP manufacturing for clinical supply amidst increasing global complexity in biopharma manufacturing, highlighting the need for enhanced local capabilities.
- Diverse Participation: Representatives from government, public agencies, international biopharma manufacturers, and investors are expected to participate, fostering in-depth dialogue and collaboration on the future development of Israel's biopharma sector.
- Strategic Importance: By discussing the infrastructure and manufacturing capabilities in Israel's biopharma sector, the roundtable aims to provide practical insights that will help companies maintain competitiveness and attract investment over the next 5-10 years.
See More
